Compare VBIX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIX | IMNN |
|---|---|---|
| Founded | N/A | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.9M |
| IPO Year | N/A | 1985 |
| Metric | VBIX | IMNN |
|---|---|---|
| Price | $1.06 | $3.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 138.7K | 53.9K |
| Earning Date | 03-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,056,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $2.99 |
| 52 Week High | $9.80 | $41.22 |
| Indicator | VBIX | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 40.20 |
| Support Level | $1.05 | $2.99 |
| Resistance Level | $1.18 | $4.00 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 28.42 | 34.56 |
ViewBix Inc operates in the field of digital advertising. Along with its subsidiaries, the company performs two main activities that are reported as separate operating segments: the search segment and the digital content segment. Maximum revenue is generated from the digital content segment, which is engaged in the creation and editing of content, in different languages, for different target audiences, to generate revenues from advertising platforms, including Google, Facebook, Yahoo, and Apple, by utilizing such content to obtain internet user traffic for its customers. The search segment develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).